




# PHARMACEUTICAL 2020

Collectar Biosciences Inc.  
Rank 231 of 358





# PHARMACEUTICAL 2020

**Collectar Biosciences Inc.**  
Rank 231 of 358

The relative strengths and weaknesses of Collectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Collectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 17% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	11,386
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,770
Liabilities, Non-Current	422
Other Assets	430
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	86
Other Revenues	0
Property and Equipment	435
Research and Development	8,996
Selling, General and Administrative Expense	5,183

Output Variable	Value in 1000 USD
Assets	12,251
Liabilities	3,191
Expenses	14,179
Revenues	0
Stockholders Equity	9,059
Net Income	-14,093
Comprehensive Net Income	-14,093
Economic Capital Ratio	19%